Evidence map›Paper›PMID 39543433›Full record

ArticleAdvanced materials (Deerfield Beach, Fla.)2024

Charge-Stabilized Nanodiscs as a New Class of Lipid Nanoparticles.

Ivan S Pires, Alexander Hostetler, Gil Covarrubias, Isabella S Carlo, Jack R Suggs, B J Kim, Andrew J Pickering, Ezra Gordon, Darrell J Irvine, Paula T Hammond

Abstract read
In one paragraph

Article in Advanced materials (Deerfield Beach, Fla.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Recent Advances and Future Prospects in Biological-Membrane-Targeted Polymers.Polymer science & technology (Washington, D.C.) · 2025
    Review
  4. Charge-Stabilized Nanodiscs as a New Class of Lipid Nanoparticles.Advanced materials (Deerfield Beach, Fla.) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ivan S PiresKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 500 Main Street, Cambridge, MA, 02139, USA.ORCID 0000-0002-4035-0027
Alexander HostetlerKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 500 Main Street, Cambridge, MA, 02139, USA.ORCID 0000-0001-6260-8765
Gil CovarrubiasKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 500 Main Street, Cambridge, MA, 02139, USA.
Isabella S CarloKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 500 Main Street, Cambridge, MA, 02139, USA.
Jack R SuggsKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 500 Main Street, Cambridge, MA, 02139, USA.
B J KimKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 500 Main Street, Cambridge, MA, 02139, USA.ORCID 0000-0001-8131-5255
Andrew J PickeringKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 500 Main Street, Cambridge, MA, 02139, USA.
Ezra GordonKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 500 Main Street, Cambridge, MA, 02139, USA.
Darrell J IrvineKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 500 Main Street, Cambridge, MA, 02139, USA.ORCID 0000-0002-8637-1405
Paula T HammondKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 500 Main Street, Cambridge, MA, 02139, USA.ORCID 0000-0002-9835-192X

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Jacqueline A. Lees · 1985 to 2026
$93.9M
Delivery of cytokines for cancer immunotherapy using nanolayer-controlled trafficking of liposomal nanoparticlesR01CA235375 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Paula T Hammond, Darrell J Irvine · 2019 to 2026
$2.3M
Development of Lipid Nanoparticles for B-cell Mediated ImmunotherapiesK00CA274651 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Ivan Susin Pires · 2025 to 2026
$180k
Engineering Next-Generation Nanoparticles One Layer at a TimeF99CA274651 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI SUSIN PIRES, IVAN · 2022 to 2023
$96k
Howard Hughes Medical InstituteNCI NIH HHS F99 CA274651NCI NIH HHS F99-CA274651NCI NIH HHS K00 CA274651NCI NIH HHS P30 CA014051NCI NIH HHS P30-CA14051NCI NIH HHS R01 CA235375NCI NIH HHS R01-CA235375Ragon Institute of MGH, MIT and Harvard
6 · The paper itself

Abstract

Nanoparticles have the potential to improve disease treatment and diagnosis due to their ability to incorporate drugs, alter pharmacokinetics, and enable tissue targeting. While considerable effort is placed on developing spherical lipid-based nanocarriers, recent evidence suggests that high aspect ratio lipid nanocarriers can exhibit enhanced disease site targeting and altered cellular interactions. However, the assembly of lipid-based nanoparticles into non-spherical morphologies has typically required incorporating additional agents such as synthetic polymers, proteins, lipid-polymer conjugates, or detergents. Here, charged lipid headgroups are used to generate stable discoidal lipid nanoparticles from mixed micelles, which are termed charge-stabilized nanodiscs (CNDs). The ability to generate CNDs in buffers with physiological ionic strength is restricted to lipids with more than one anionic group, whereas monovalent lipids only generate small nanoliposomal assemblies. In mice, the smaller size and anisotropic shape of CNDs promote higher accumulation in subcutaneous tumors than spherical liposomes. Further, the surface chemistry of CNDs can be modified via layer-by-layer (LbL) assembly to improve their tumor-targeting properties over state-of-the-art LbL-liposomes when tested using a metastatic model of ovarian cancer. The application of charge-mediated anisotropy in lipid-based assemblies can aid in the future design of biomaterials and cell-membrane mimetic structures.

Indexed as

NanoparticlesAnimalsCell Line, TumorDrug CarriersFemaleHumansLipidsLiposomesMiceMicellesStatic ElectricityDrug CarriersLipid NanoparticlesLipidsLiposomesMicellesanisotropylayer‐by‐layerlipid nanoparticlesnanodiscsself‐assemblytumor targeting

Identifiers

PMID39543433
PMCPMC11681300

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.